Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-Site Botulinum Toxin Type A for Lifelong Premature Ejaculation
NCT07426640Completed
- Sponsor
- Al Mouwasat Medical Services
- Start
- Nov 2021
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in premature ejaculation (PE) comparing BOTULINUM TOXIN TYPE A with placebo (2 arms). Primary endpoint: Intravaginal Ejaculatory Latency Time at 6 months. Started Nov 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on NCT07426640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07426640.